soul trial oral semaglutide cardiovascular outcomes 2024 results mace and in High-Risk Type 2 Diabetes Oral Semaglutide Reduces CV Events

Name: soul trial oral semaglutide cardiovascular outcomes 2024 results mace and in High-Risk Type 2 Diabetes Oral Semaglutide Reduces CV Events
Brand: www.cleversources.com
SKU: 74093771377
Price: 29.08 USD
Availability: InStock
Rating: 4.3519000000000005 (9 reviews)

SKU: 74093771377

4.4

USD29.08 USD53.08

Pay in 4 interest-free payments of $7.27 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Live Spec

Oral Semaglutide Reduces CV Events in T2DM SOUL Trial (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine T2DM + ASCVD CKD Oral semaglutide 14 mg vs placebo Oral semaglutide (14 mg) demonstrates superior reduction in cardiovascular events Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial Semaglutide significantly reduced the risk of CV death MI stroke regardless of baseline CKD severity in participants Cardiovascular Outcomes Associated with Semaglutide in Type 2 Diabetes: A Systematic Review and Meta Analysis

Store: www.cleversources.com · Domain: www.cleversources.com

Description

This accountability is a major difference compared to self-directed diets